JPWO2020076789A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020076789A5 JPWO2020076789A5 JP2021519612A JP2021519612A JPWO2020076789A5 JP WO2020076789 A5 JPWO2020076789 A5 JP WO2020076789A5 JP 2021519612 A JP2021519612 A JP 2021519612A JP 2021519612 A JP2021519612 A JP 2021519612A JP WO2020076789 A5 JPWO2020076789 A5 JP WO2020076789A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- aureus
- binding fragment
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004965 antibodies Human genes 0.000 claims description 365
- 108090001123 antibodies Proteins 0.000 claims description 365
- 239000000427 antigen Substances 0.000 claims description 362
- 108091007172 antigens Proteins 0.000 claims description 362
- 102000038129 antigens Human genes 0.000 claims description 362
- 239000000203 mixture Substances 0.000 claims description 129
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 95
- 101700015696 PHL12 Proteins 0.000 claims description 92
- 101700005515 SCX Proteins 0.000 claims description 92
- 239000002776 alpha toxin Substances 0.000 claims description 92
- 101700027420 hly Proteins 0.000 claims description 92
- 101700005116 plc Proteins 0.000 claims description 92
- 101700017245 clfA Proteins 0.000 claims description 66
- XEBKSQSGNGRGDW-YFHOEESVSA-N 9,10-DiHOME Chemical compound CCCCC\C=C/CC(O)C(O)CCCCCCCC(O)=O XEBKSQSGNGRGDW-YFHOEESVSA-N 0.000 claims description 56
- 101700070063 lktA Proteins 0.000 claims description 55
- 101700063372 ltxA Proteins 0.000 claims description 55
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims description 43
- 208000008960 Diabetic Foot Diseases 0.000 claims description 19
- 230000035693 Fab Effects 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 230000035772 mutation Effects 0.000 claims description 11
- 206010012601 Diabetes mellitus Diseases 0.000 claims description 10
- 206010035664 Pneumonia Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 230000002458 infectious Effects 0.000 claims description 8
- 230000036499 Half live Effects 0.000 claims description 7
- 102000018358 Immunoglobulins Human genes 0.000 claims description 7
- 108060003951 Immunoglobulins Proteins 0.000 claims description 7
- 206010031252 Osteomyelitis Diseases 0.000 claims description 7
- 206010062255 Soft tissue infection Diseases 0.000 claims description 7
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 7
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 7
- 206010060968 Arthritis infective Diseases 0.000 claims description 6
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims description 6
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims description 6
- 150000002019 disulfides Chemical class 0.000 claims description 6
- 206010003997 Bacteraemia Diseases 0.000 claims description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
- 210000003141 Lower Extremity Anatomy 0.000 claims description 4
- 206010048038 Wound infection Diseases 0.000 claims description 4
- 238000004220 aggregation Methods 0.000 claims description 4
- 230000002776 aggregation Effects 0.000 claims description 4
- 230000003115 biocidal Effects 0.000 claims description 4
- 206010040872 Skin infection Diseases 0.000 claims description 3
- 231100000765 Toxin Toxicity 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 229940076185 Staphylococcus aureus Drugs 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 230000003628 erosive Effects 0.000 claims description 2
- 238000005755 formation reaction Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000003902 lesions Effects 0.000 claims description 2
- 230000001662 opsonic Effects 0.000 claims description 2
- 206010064687 Device related infection Diseases 0.000 claims 2
- 230000005591 charge neutralization Effects 0.000 claims 1
- 230000001264 neutralization Effects 0.000 claims 1
- 238000006386 neutralization reaction Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004851 Immunoglobulin G Human genes 0.000 description 19
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 229940012952 Fibrinogen Drugs 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 229940019698 Fibrinogen containing hemostatics Drugs 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 2
- 108020003112 toxins Proteins 0.000 description 2
- 102100014838 FCGRT Human genes 0.000 description 1
- 101710003435 FCGRT Proteins 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 230000003472 neutralizing Effects 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
Description
本発明の実施形態を下記項にさらに記載する:
[項1]
対象における黄色ブドウ球菌(Staphylococcus aureus(S.aureus))感染症を治療又は予防する方法であって、前記被験者に(a)黄色ブドウ球菌(S.aureus)α毒素(AT)に結合する抗体若しくはその抗原結合断片、(b)黄色ブドウ球菌(S.aureus)クランピング因子A(ClfA)に結合する抗体若しくはその抗原結合断片、及び(c)少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する抗体若しくはその抗原結合断片を投与するステップを含む方法。
[項2]
対象における黄色ブドウ球菌(S.aureus)感染症を治療又は予防する方法であって、前記被験者に少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する抗体若しくはその抗原結合断片及び(a)黄色ブドウ球菌(S.aureus)α毒素(AT)に結合する抗体若しくはその抗原結合断片又は(b)黄色ブドウ球菌(S.aureus)クランピング因子A(ClfA)に結合する抗体若しくはその抗原結合断片を投与するステップを含む方法。
[項3]
(a)黄色ブドウ球菌(S.aureus)ATに結合する抗体若しくはその抗原結合断片、(b)黄色ブドウ球菌(S.aureus)ClfAに結合する抗体若しくはその抗原結合断片、及び(c)少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する抗体若しくはその抗原結合断片を含む組成物。
[項4]
少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する抗体若しくはその抗原結合断片及び(a)黄色ブドウ球菌(S.aureus)ATに結合する抗体若しくはその抗原結合断片又は(b)黄色ブドウ球菌(S.aureus)ClfAに結合する抗体若しくはその抗原結合断片を含む組成物。
[項5]
対象における黄色ブドウ球菌(S.aureus)感染症を治療又は予防する際に使用するための、上記項3又は4に記載の組成物。
[項6]
対象における黄色ブドウ球菌(S.aureus)感染症を治療又は予防する際に使用するための、黄色ブドウ球菌(S.aureus)ClfAに結合する抗体若しくはその抗原結合断片及び少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する抗体若しくはその抗原結合断片と組み合わせた、黄色ブドウ球菌(S.aureus)α毒素(AT)に結合する抗体若しくはその抗原結合断片。
[項7]
対象における黄色ブドウ球菌(S.aureus)感染症を治療又は予防する際に使用するための、黄色ブドウ球菌(S.aureus)ATに結合する抗体若しくはその抗原結合断片及び少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する抗体若しくはその抗原結合断片と組み合わせた、黄色ブドウ球菌(S.aureus)ClfAに結合する抗体若しくはその抗原結合断片。
[項8]
対象における黄色ブドウ球菌(S.aureus)感染症を治療又は予防する際に使用するための、黄色ブドウ球菌(S.aureus)ATに結合する抗体若しくはその抗原結合断片及び/又は黄色ブドウ球菌(S.aureus)ClfAに結合する抗体若しくはその抗原結合断片と組み合わせた、少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する抗体若しくはその抗原結合断片。
[項9]
対象における黄色ブドウ球菌(S.aureus)感染症を治療又は予防するための医薬品の調製における、上記項3又は4に記載の組成物の使用。
[項10]
対象における黄色ブドウ球菌(S.aureus)感染症を治療又は予防するための医薬品の調製における、黄色ブドウ球菌(S.aureus)ClfAに結合する抗体若しくはその抗原結合断片及び少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する抗体若しくはその抗原結合断片と組み合わせた、黄色ブドウ球菌(S.aureus)α毒素(AT)に結合する抗体若しくはその抗原結合断片の使用。
[項11]
対象における黄色ブドウ球菌(S.aureus)感染症を治療又は予防するための医薬品の調製における、黄色ブドウ球菌(S.aureus)ATに結合する抗体若しくはその抗原結合断片及び少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する抗体若しくはその抗原結合断片と組み合わせた、黄色ブドウ球菌(S.aureus)ClfAに結合する抗体若しくはその抗原結合断片の使用。
[項12]
対象における黄色ブドウ球菌(S.aureus)感染症を治療又は予防するための医薬品の調製における、黄色ブドウ球菌(S.aureus)ATに結合する抗体若しくはその抗原結合断片及び/又は黄色ブドウ球菌(S.aureus)ClfAに結合する抗体若しくはその抗原結合断片と組み合わせた、少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する抗体若しくはその抗原結合断片の使用。
[項13]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、配列番号19の前記アミノ酸配列を含むVH及び配列番号33の前記アミノ酸配列を含むVLを含む抗体と前記同じ黄色ブドウ球菌(S.aureus)ATエピトープに結合する、上記項1~12の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項14]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、配列番号19の前記アミノ酸配列を含むVH及び配列番号33の前記アミノ酸配列を含むVLを含む抗体の黄色ブドウ球菌(S.aureus)ATへの結合を競合的に阻害する、上記項1~13の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項15]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、配列番号1の前記アミノ酸配列を含む可変重鎖(VH)相補性決定領域(CDR)1、配列番号2の前記アミノ酸配列を含むVH CDR2、配列番号3の前記アミノ酸配列を含むVH CDR3、配列番号10の前記アミノ酸配列を含む可変軽鎖(VL)CDR1、配列番号11の前記アミノ酸配列を含むVL CDR2及び配列番号12の前記アミノ酸配列を含むVL CDR3を含む、上記項1~14の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項16]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、配列番号19の前記アミノ酸配列を含むVHを含む、上記項1~15の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項17]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、配列番号33の前記アミノ酸配列を含むVLを含む、上記項1~16の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項18]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、配列番号47の前記アミノ酸配列を含む重鎖を含む、上記項1~17の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項19]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、配列番号52の前記アミノ酸配列を含む軽鎖を含む、上記項1~18の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項20]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、MEDI4893のVH CDR1、VH CDR2、VH CDR3、VL CDR1、VL CDR2及びVL CDR3を含む、上記項1~14の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項21]
前記CDRは、Kabat定義CDR、Chothia定義CDR又はAbM定義CDRである、上記項20に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項22]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、重鎖定常領域を更に含む、上記項1~17及び19~21の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項23]
前記重鎖定常領域は、ヒト免疫グロブリンIgG1、IgG2、IgG3、IgG4、IgA1及びIgA2重鎖定常領域から成る群から選択される、上記項22に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項24]
前記重鎖定常領域は、ヒトIgG1定常領域である、上記項22に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項25]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、軽鎖定常領域を更に含む、上記項1~18、20及び21の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項26]
前記軽鎖定常領域は、ヒト免疫グロブリンIgGκ及びIgGλ軽鎖定常領域から成る群から選択される、上記項25に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項27]
前記軽鎖定常領域は、ヒトIgGκ軽鎖定常領域である、上記項25に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項28]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、IgG抗体若しくはその抗原結合断片である、上記項1~27の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項29]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、半減期を改善するために遺伝子組み換えされているFc領域を含む、上記項1~28の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項30]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、YTE突然変異を有するFc領域を含む、上記項1~29の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項31]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、モノクローナル抗体若しくは抗原結合断片である、上記項1~30の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項32]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、完全長抗体である、上記項1~31の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項33]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、抗原結合断片である、上記項1~31の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項34]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、Fab、Fab’、F(ab’)2、単鎖Fv(scFv)、ジスルフィド連結Fv、イントラボディ、IgGΔCH2、ミニボディ、F(ab’)3、テトラボディ、トリアボディ、ダイアボディ、DVD-Ig、Fcab、mAb2、(scFv)2又はscFv-Fcを含む、上記項33に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項35]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、黄色ブドウ球菌(S.aureus)ATに対して80~100pMの親和性を有する、上記項1~34の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項36]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、配列番号20の前記アミノ酸配列を含むVH及び配列番号34の前記アミノ酸配列を含むVLを含む抗体と前記同じ黄色ブドウ球菌(S.aureus)ClfAエピトープに結合する、上記項1~35の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項37]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、配列番号20の前記アミノ酸配列を含むVH及び配列番号34の前記アミノ酸配列を含むVLを含む抗体の黄色ブドウ球菌(S.aureus)ClfAへの結合を競合的に阻害する、上記項1~36の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項38]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくは抗原結合断片は、配列番号4の前記アミノ酸配列を含むVH CDR1、配列番号5の前記アミノ酸配列を含むVH CDR2、配列番号6の前記アミノ酸配列を含むVH CDR3、配列番号13の前記アミノ酸配列を含むVL CDR1、配列番号14の前記アミノ酸配列を含むVL CDR2及び配列番号15の前記アミノ酸配列を含むVL CDR3を含む、上記項1~37の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項39]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、配列番号20の前記アミノ酸配列を含むVHを含む、上記項1~38の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項40]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、配列番号34の前記アミノ酸配列を含むVLを含む、上記項1~39の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項41]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、CSYHLC(配列番号55)の前記アミノ酸配列を含む重鎖定常ドメインを含む、上記項1~40の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項42]
前記重鎖定常ドメインは、MHEACSYHLCQKSLSLS(配列番号56)の前記アミノ酸配列を含む、上記項41に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項43]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、配列番号49の前記アミノ酸配列を含む重鎖を含む、上記項1~42の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項44]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、配列番号53の前記アミノ酸配列を含む軽鎖を含む、上記項1~43の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項45]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、SAR114-N3YのVH CDR1、VH CDR2、VH CDR3、VL CDR1、VL CDR2及びVL CDR3を含む、上記項1~44の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項46]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、11H10、SAR72、SAR80、SAR113、SAR132、SAR352、SAR372、SAR510、SAR547、SAS1、SAS19又はSAS203のVH CDR1、VH CDR2、VH CDR3、VL CDR1、VL CDR2及びVL CDR3を含む、上記項1~35の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項47]
前記CDRは、Kabat定義CDR、Chothia定義CDR又はAbM定義CDRである、上記項45又は46に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項48]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、VH及びVLを含み、ここで前記VHは配列番号21~31及び68の何れか1つに記載の前記アミノ酸配列を含む、上記項1~35又は46の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項49]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、VH及びVLを含み、前記VLは、配列番号35~45及び69の何れか1つに記載の前記アミノ酸配列を含む、上記項1~35又は46の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項50]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、(a)それぞれ配列番号21及び35、(b)それぞれ配列番号22及び36、(c)それぞれ配列番号23及び37、(d)それぞれ配列番号24及び38、(e)それぞれ配列番号25及び39、(f)それぞれ配列番号26及び40、(g)それぞれ配列番号27及び41、(h)それぞれ配列番号28及び42、(i)それぞれ配列番号29及び43、(j)それぞれ配列番号30及び44、(k)それぞれ配列番号31及び45又は(l)それぞれ配列番号68及び69に記載した前記アミノ酸配列を含むVH及びVL配列を含む、上記項1~35の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項51]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、重鎖定常領域を更に含む、上記項1~40及び44~50の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項52]
前記重鎖定常領域は、ヒト免疫グロブリンIgG1、IgG2、IgG3、IgG4、IgA1及びIgA2重鎖定常領域から成る群から選択される、上記項51に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項53]
前記重鎖定常領域は、ヒトIgG1定常領域である、上記項51に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項54]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、軽鎖定常領域を更に含む、上記項1~43及び45~53の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項55]
前記軽鎖定常領域は、ヒト免疫グロブリンIgGκ及びIgGλ軽鎖定常領域から成る群から選択される、上記項54に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項56]
前記軽鎖定常領域は、ヒトIgGκ軽鎖定常領域である、上記項54に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項57]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくは抗原結合断片は、ヒトFcRnマウスにおいて前記突然変異を伴わない前記同じ抗体と比較して半減期を延長する突然変異を含む、上記項1~56の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項58]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、前記突然変異を伴わない前記同じ抗体と比較して半減期を延長する突然変異を含み、前記突然変異は、前記突然変異を伴わない前記同じ抗体若しくは抗原結合断片と比較して、OPK活性を阻害しない、上記項1~57の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項59]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、モノクローナル抗体若しくは抗原結合断片である、上記項1~58の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項60]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、完全長抗体である、上記項1~59の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項61]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、抗原結合断片である、上記項1~59の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項62]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、Fab、Fab’、F(ab’)2、単鎖Fv(scFv)、ジスルフィド連結Fv、イントラボディ、IgGΔCH2、ミニボディ、F(ab’)3、テトラボディ、トリアボディ、ダイアボディ、DVD-Ig、Fcab、mAb2、(scFv)2又はscFv-Fcを含む、上記項61に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項63]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、フィブリノーゲン結合阻害アッセイにおいて、ClfA001、ClfA002及びClfA004に対して相互に2μg/mL以内にあるIC50を有する、上記項1~62の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項64]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、フィブリノーゲン結合阻害アッセイにおいて、ClfA001、ClfA002及びClfA004に対して全部が1μg/mL~5μg/mLの間にあるIC50を有する、上記項1~63の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項65]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、ClfA001、ClfA002及びClfA004に対する、全部が200~350pMの間にある結合親和性(KD)を有する、上記項1~64の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項66]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、全ClfA遺伝子型に対して1nM未満の結合親和性(KD)を有する、上記項1~65の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項67]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくは抗原結合断片は、前記抗体若しくは抗原結合断片を従来の白色光に2kLux/時で23℃にて14日間曝露した後に5%以下低下するモノマー純度を有する、上記項1~66の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項68]
少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、LukF、LukD及び/又はHlgBに結合する、及び/又は前記抗体若しくはその抗原結合断片は、LukF、LukD及び/又はHlgBを中和する、上記項1~67の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項69]
少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、LukF、LukD及び/又はHlgBに結合する、及び/又は前記抗体若しくはその抗原結合断片は、LukF、LukD及び/又はHlgBを中和する、上記項68に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項70]
黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、配列番号32の前記アミノ酸配列を含むVH及び配列番号46の前記アミノ酸配列を含むVLを含む抗体と前記同じ黄色ブドウ球菌(S.aureus)ロイコトキシンエピトープに結合する、上記項1~69の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項71]
黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、配列番号32の前記アミノ酸配列を含むVH及び配列番号46の前記アミノ酸配列を含むVLを含む抗体の前記黄色ブドウ球菌(S.aureus)ロイコトキシンへの結合を競合的に阻害する、上記項1~70の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項72]
少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくは抗原結合断片は、配列番号7の前記アミノ酸配列を含むVHCDR1、配列番号8の前記アミノ酸配列を含むVH CDR2、配列番号9の前記アミノ酸配列を含むVH CDR3、配列番号16の前記アミノ酸配列を含むVL CDR1、配列番号17の前記アミノ酸配列を含むVL CDR2及び配列番号18の前記アミノ酸配列を含むVL CDR3を含む、上記項1~71の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項73]
少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、配列番号32の前記アミノ酸配列を含むVHを含む、上記項1~72の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項74]
少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、配列番号46の前記アミノ酸配列を含むVLを含む、上記項1~73の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項75]
少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、配列番号50の前記アミノ酸配列を含む重鎖を含む、上記項1~74の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項76]
少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、配列番号54の前記アミノ酸配列を含む軽鎖を含む、上記項1~75の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項77]
少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、SAN481-SYTのVH CDR1、VH CDR2、VH CDR3、VL CDR1、VL CDR2及びVL CDR3を含む、上記項1~71の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項78]
前記CDRは、Kabat定義CDR、Chothia定義CDR又はAbM定義CDRである、上記項77に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項79]
少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、重鎖定常領域を更に含む、上記項1~74及び76~78の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項80]
前記重鎖定常領域は、ヒト免疫グロブリンIgG1、IgG2、IgG3、IgG4、IgA1及びIgA2重鎖定常領域から成る群から選択される、上記項79に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項81]
前記重鎖定常領域は、ヒトIgG1定常領域である、上記項79に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項82]
少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、軽鎖定常領域を更に含む、上記項1~75及び77~81の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項83]
前記軽鎖定常領域は、ヒト免疫グロブリンIgGκ及びIgGλ軽鎖定常領域から成る群から選択される、上記項82に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項84]
前記軽鎖定常領域は、ヒトIgGκ軽鎖定常領域である、上記項82に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項85]
少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、IgG抗体若しくはその抗原結合断片である、上記項1~84の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項86]
少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、半減期を改善するために遺伝子組み換えされているFc領域を含む、上記項1~85の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項87]
少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、YTE突然変異を有するFc領域を含む、上記項1~86の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項88]
少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、モノクローナル抗体若しくはその抗原結合断片である、上記項1~87の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項89]
少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、完全長抗体である、上記項1~88の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項90]
少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、抗原結合断片である、上記項1~88の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項91]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、Fab、Fab’、F(ab’)2、単鎖Fv(scFv)、ジスルフィド連結Fv、イントラボディ、IgGΔCH2、ミニボディ、F(ab’)3、テトラボディ、トリアボディ、ダイアボディ、DVD-Ig、Fcab、mAb2、(scFv)2又はscFv-Fcを含む、上記項90に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項92]
少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、黄色ブドウ球菌(S.aureus)LukF、LukD及びH1gBに対して75pM未満の親和性を有する、上記項1~91の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項93]
少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、LukF、LukD及びHIgBに対して類似の親和性を有する、上記項1~92の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項94]
前記黄色ブドウ球菌(S.aureus)感染症は、敗血症である、上記項1、2及び5~93の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項95]
前記黄色ブドウ球菌(S.aureus)感染症は、菌血症である、上記項1、2及び5~93の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項96]
前記黄色ブドウ球菌(S.aureus)感染症は、肺炎である、上記項1、2及び5~93の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項97]
前記黄色ブドウ球菌(S.aureus)感染症は、ICU肺炎である、上記項1、2及び5~93の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項98]
前記黄色ブドウ球菌(S.aureus)感染症は、皮膚若しくは軟組織感染症(SSTI)である、上記項1、2及び5~93の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項99]
前記黄色ブドウ球菌(S.aureus)感染症は、下肢の糖尿病性感染症である、上記項1、2及び5~93の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項100]
前記黄色ブドウ球菌(S.aureus)感染症は、糖尿病性足部潰瘍(DFU)である、上記項1、2及び5~93の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項101]
前記DFUは、非感染性である、上記項100に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項102]
前記DFUは、感染性である、上記項100に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項103]
前記DFUは、グレード1、2又は3のDFUである、上記項100に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項104]
前記黄色ブドウ球菌(S.aureus)感染症は、骨又は関節感染症である、上記項1、2及び5~93の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項105]
前記黄色ブドウ球菌(S.aureus)感染症は、関節感染症、デバイス関連感染症、創傷感染症、手術部位感染症又は骨髄炎である、上記項1、2及び5~93の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項106]
前記対象は、外科患者である、上記項1、2及び5~105の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項107]
前記黄色ブドウ球菌(S.aureus)感染症は、抗生物質耐性黄色ブドウ球菌(S.aureus)を含む、上記項1、2及び5~106の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項108]
前記対象は、糖尿病を有する、上記項1、2及び5~107の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項109]
前記対象は、ヒトである、上記項1、2及び5~108の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項110]
黄色ブドウ球菌(S.aureus)感染症を前記治療又は予防するステップは、黄色ブドウ球菌(S.aureus)の凝集を阻害するステップ、毒素中和、オプソニン浸食作用を誘導するステップ、黄色ブドウ球菌(S.aureus)のフィブリノーゲン結合を阻害するステップ、黄色ブドウ球菌(S.aureus)の凝集を阻害するステップ、血栓塞栓性病巣形成を阻害するステップ、黄色ブドウ球菌(S.aureus)関連性敗血症を阻害するステップ又は上記の任意の組み合わせを含む、上記項1、2及び5~109の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項111]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片及び黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、前記同じ医薬組成物中で投与される、上記項1、2、6~8及び10~110の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項112]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片及び黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片は、前記別個の医薬組成物中で投与される、上記項1、2、6~8及び10~110の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項113]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片及び少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、前記同じ医薬組成物中で投与される、上記項1、2、6~8及び10~110の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項114]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片及び少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、前記別個の医薬組成物中で投与される、上記項1、2、6~8及び10~110の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項115]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片及び少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、前記同じ医薬組成物中で投与される、上記項1、2、6~8及び10~110の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項116]
黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片及び少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、前記別個の医薬組成物中で投与される、上記項1、2、6~8及び10~110の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項117]
前記別個の医薬組成物は、同時に投与される、上記項112、114及び116の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項118]
前記別個の医薬組成物は、連続的に投与される、上記項112、114及び116の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項119]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片、黄色ブドウ球菌(S.aureus)ClfAに結合する前記抗体若しくはその抗原結合断片及び少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する前記抗体若しくはその抗原結合断片は、前記同じ医薬組成物中で投与される、上記項1、2、6~8及び10~110の何れか一項に記載の方法、組成物、抗体若しくはその抗原結合断片又は使用。
[項120]
糖尿病を有する対象における黄色ブドウ球菌(S.aureus)感染症を治療又は予防する方法であって、前記対象に黄色ブドウ球菌(S.aureus)ATに結合する抗体若しくはその抗原結合断片を投与するステップを含む方法。
[項121]
糖尿病を有する対象における黄色ブドウ球菌(S.aureus)感染症を治療又は予防する際に使用するための、黄色ブドウ球菌(S.aureus)ATに結合する抗体若しくはその抗原結合断片。
[項122]
糖尿病を有する対象における黄色ブドウ球菌(S.aureus)感染症を治療又は予防するための医薬品の前記調製における、黄色ブドウ球菌(S.aureus)ATに結合する抗体若しくはその抗原結合断片の使用。
[項123]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、配列番号19の前記アミノ酸配列を含むVH及び配列番号33の前記アミノ酸配列を含むVLを含む抗体と前記同じ黄色ブドウ球菌(S.aureus)ATエピトープに結合する、上記項120~122の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項124]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、配列番号19の前記アミノ酸配列を含むVH及び配列番号33の前記アミノ酸配列を含むVLを含む抗体の黄色ブドウ球菌(S.aureus)ATへの結合を競合的に阻害する、上記項120~123の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項125]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくは抗原結合断片は、配列番号1の前記アミノ酸配列を含むVH CDR1、配列番号2の前記アミノ酸配列を含むVH CDR2、配列番号3の前記アミノ酸配列を含むVH CDR3、配列番号10の前記アミノ酸配列を含むVL CDR1、配列番号11の前記アミノ酸配列を含むVL CDR2及び配列番号12の前記アミノ酸配列を含むVL CDR3を含む、上記項120~124の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項126]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、配列番号19の前記アミノ酸配列を含むVHを含む、上記項120~125の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項127]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、配列番号33の前記アミノ酸配列を含むVLを含む、上記項120~126の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項128]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、配列番号47の前記アミノ酸配列を含む重鎖を含む、上記項120~127の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項129]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、配列番号52の前記アミノ酸配列を含む軽鎖を含む、上記項120~128の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項130]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、MEDI4893のVH CDR1、VH CDR2、VH CDR3、VL CDR1、VL CDR2及びVL CDR3を含む、上記項120~124の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項131]
前記CDRは、Kabat定義CDR、Chothia定義CDR又はAbM定義CDRである、上記項130に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項132]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、重鎖定常領域を更に含む、上記項120~127及び129~131の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項133]
前記重鎖定常領域は、ヒト免疫グロブリンIgG1、IgG2、IgG3、IgG4、IgA1及びIgA2重鎖定常領域から成る群から選択される、上記項132に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項134]
前記重鎖定常領域は、ヒトIgG1定常領域である、上記項132に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項135]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、軽鎖定常領域を更に含む、上記項120~128及び130~134の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項136]
前記軽鎖定常領域は、ヒト免疫グロブリンIgGκ及びIgGλ軽鎖定常領域から成る群から選択される、上記項135に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項137]
前記軽鎖定常領域は、ヒトIgGκ軽鎖定常領域である、上記項135に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項138]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、IgG抗体若しくはその抗原結合断片である、上記項120~137の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項139]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、半減期を改善するために遺伝子組み換えされているFc領域を含む、上記項120~138の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項140]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、YTE突然変異を有するFc領域を含む、上記項120~139の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項141]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、モノクローナル抗体若しくは抗原結合断片である、上記項120~140の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項142]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、完全長抗体である、上記項120~141の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項143]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、抗原結合断片である、上記項120~141の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項144]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、Fab、Fab’、F(ab’)2、単鎖Fv(scFv)、ジスルフィド連結Fv、イントラボディ、IgGΔCH2、ミニボディ、F(ab’)3、テトラボディ、トリアボディ、ダイアボディ、DVD-Ig、Fcab、mAb2、(scFv)2又はscFv-Fcを含む、上記項143に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項145]
黄色ブドウ球菌(S.aureus)ATに結合する前記抗体若しくはその抗原結合断片は、黄色ブドウ球菌(S.aureus)ATに対して80~100pMの親和性を有する、上記項120~144の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項146]
前記黄色ブドウ球菌(S.aureus)感染症は、敗血症である、上記項120~145の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項147]
前記黄色ブドウ球菌(S.aureus)感染症は、菌血症である、上記項120~145の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項148]
前記黄色ブドウ球菌(S.aureus)感染症は、肺炎である、上記項120~145の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項149]
前記黄色ブドウ球菌(S.aureus)感染症は、ICU肺炎である、上記項120~145の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項150]
前記黄色ブドウ球菌(S.aureus)感染症は、SSTIである、上記項120~145の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項151]
前記黄色ブドウ球菌(S.aureus)感染症は、下肢の糖尿病性感染症である、上記項120~145の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項152]
前記黄色ブドウ球菌(S.aureus)感染症は、DFUである、上記項120~145の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項153]
前記DFUは、非感染性である、上記項152に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項154]
前記DFUは、感染性である、上記項152に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項155]
前記DFUは、グレード1、2又は3のDFUである、上記項154に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項156]
前記黄色ブドウ球菌(S.aureus)感染症は、骨又は関節感染症である、上記項及び120~145の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項157]
前記黄色ブドウ球菌(S.aureus)感染症は、関節感染症、デバイス関連感染症、創傷感染症、手術部位感染症又は骨髄炎である、上記項120~145の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項158]
前記対象は、外科患者である、上記項120~157の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項159]
前記黄色ブドウ球菌(S.aureus)感染症は、抗生物質耐性黄色ブドウ球菌(S.aureus)を含む、上記項120~158の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
[項160]
前記対象は、ヒトである、上記項120~159の何れか一項に記載の方法、抗体若しくはその抗原結合断片又は使用。
以下の実施例は、本発明を更に説明するが、当然ながら、決してその範囲を制限するものであると解釈されるべきではない。
Embodiments of the invention are further described in the following sections:
[Section 1]
A method of treating or preventing a Staphylococcus aureus (S. aureus) infection in a subject, comprising administering to the subject (a) an antibody that binds S. aureus alpha-toxin (AT) or an antigen-binding fragment thereof, (b) an antibody or antigen-binding fragment thereof that binds to S. aureus clumping factor A (ClfA), and (c) at least one S. aureus leuco A method comprising administering an antibody or antigen-binding fragment thereof that binds a toxin.
[Section 2]
A method of treating or preventing S. aureus infection in a subject, comprising administering to said subject at least one antibody or antigen-binding fragment thereof that binds to S. aureus leukotoxin and ( a) an antibody or antigen-binding fragment thereof that binds to S. aureus alpha-toxin (AT) or (b) an antibody that binds to S. aureus clumping factor A (ClfA) or an antigen thereof A method comprising administering a binding fragment.
[Section 3]
(a) an antibody or antigen-binding fragment thereof that binds to S. aureus AT, (b) an antibody or antigen-binding fragment thereof that binds to S. aureus ClfA, and (c) at least one A composition comprising an antibody or antigen-binding fragment thereof that binds to S. aureus leukotoxin.
[Section 4]
at least one antibody or antigen-binding fragment thereof that binds to S. aureus leukotoxin and (a) an antibody or antigen-binding fragment thereof that binds to S. aureus AT or (b) yellow A composition comprising an antibody or antigen-binding fragment thereof that binds to S. aureus ClfA.
[Section 5]
5. The composition of paragraphs 3 or 4, above, for use in treating or preventing S. aureus infection in a subject.
[Section 6]
An antibody or antigen-binding fragment thereof that binds S. aureus ClfA and at least one species of S. aureus for use in treating or preventing S. aureus infection in a subject An antibody or antigen-binding fragment thereof that binds to S. aureus alpha-toxin (AT) in combination with an antibody or antigen-binding fragment thereof that binds to (S. aureus) leukotoxin.
[Section 7]
An antibody or antigen-binding fragment thereof that binds S. aureus AT and at least one species of S. aureus for use in treating or preventing S. aureus infection in a subject An antibody or antigen-binding fragment thereof that binds to S. aureus ClfA in combination with an antibody or antigen-binding fragment thereof that binds to (S. aureus) leukotoxin.
[Item 8]
An antibody or antigen-binding fragment thereof that binds S. aureus AT and/or S. aureus (S. aureus) for use in treating or preventing S. aureus infection in a subject at least one antibody or antigen-binding fragment thereof that binds to S. aureus leukotoxin in combination with an antibody or antigen-binding fragment thereof that binds to ClfA.
[Item 9]
5. Use of the composition of paragraphs 3 or 4 above in the preparation of a medicament for treating or preventing S. aureus infection in a subject.
[Item 10]
An antibody or antigen-binding fragment thereof that binds S. aureus ClfA and at least one species of S. aureus in the preparation of a medicament for treating or preventing S. aureus infection in a subject Use of an antibody or antigen-binding fragment thereof that binds to S. aureus alpha-toxin (AT) in combination with an antibody or antigen-binding fragment thereof that binds to (S. aureus) leukotoxin.
[Item 11]
An antibody or antigen-binding fragment thereof that binds S. aureus AT and at least one species of S. aureus in the preparation of a medicament for treating or preventing S. aureus infection in a subject Use of an antibody or antigen-binding fragment thereof that binds to S. aureus ClfA in combination with an antibody or antigen-binding fragment thereof that binds to (S. aureus) leukotoxin.
[Item 12]
An antibody or antigen-binding fragment thereof that binds S. aureus AT and/or S. aureus (S. aureus) in the preparation of a medicament for treating or preventing S. aureus infection in a subject Use of at least one antibody or antigen-binding fragment thereof that binds to S. aureus leukotoxin in combination with an antibody or antigen-binding fragment thereof that binds to ClfA.
[Item 13]
The antibody or antigen-binding fragment thereof that binds to S. aureus AT is the same S. aureus antibody as the antibody comprising a VH comprising the amino acid sequence of SEQ ID NO: 19 and a VL comprising the amino acid sequence of SEQ ID NO: 33. 13. The method, composition, antibody or antigen-binding fragment thereof or use of any one of the preceding clauses 1-12, which binds to a S. aureus AT epitope.
[Item 14]
The antibody or antigen-binding fragment thereof that binds to S. aureus AT is a S. aureus antibody comprising a VH comprising said amino acid sequence of SEQ ID NO: 19 and a VL comprising said amino acid sequence of SEQ ID NO: 33 ( 14. The method, composition, antibody or antigen-binding fragment thereof, or use of any one of paragraphs 1 to 13, which competitively inhibits binding to S. aureus AT.
[Item 15]
Said antibody or antigen-binding fragment thereof that binds to S. aureus AT comprises a variable heavy chain (VH) complementarity determining region (CDR) 1 comprising said amino acid sequence of SEQ ID NO: 1, said a VH CDR2 comprising an amino acid sequence, a VH CDR3 comprising said amino acid sequence of SEQ ID NO: 3, a variable light chain (VL) CDR1 comprising said amino acid sequence of SEQ ID NO: 10, a VL CDR2 comprising said amino acid sequence of SEQ ID NO: 11 and SEQ ID NO: 15. A method, composition, antibody or antigen-binding fragment thereof or use according to any one of the preceding paragraphs, comprising a VL CDR3 comprising said 12 amino acid sequences.
[Item 16]
16. The method or composition of any one of items 1 to 15, wherein the antibody or antigen-binding fragment thereof that binds to S. aureus AT comprises a VH comprising the amino acid sequence of SEQ ID NO: 19. products, antibodies or antigen-binding fragments thereof or uses.
[Item 17]
17. The method or composition of any one of items 1 to 16, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus AT comprises a VL comprising said amino acid sequence of SEQ ID NO: 33. products, antibodies or antigen-binding fragments thereof or uses.
[Item 18]
18. The method of any one of paragraphs 1 to 17, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus AT comprises a heavy chain comprising said amino acid sequence of SEQ ID NO:47. Compositions, antibodies or antigen-binding fragments thereof or uses.
[Item 19]
19. The method of any one of paragraphs 1 to 18, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus AT comprises a light chain comprising said amino acid sequence of SEQ ID NO:52. Compositions, antibodies or antigen-binding fragments thereof or uses.
[Section 20]
15. Any of paragraphs 1 to 14 above, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus AT comprises VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 of MEDI4893. A method, composition, antibody or antigen-binding fragment thereof, or use according to any one of claims 1 to 3.
[Section 21]
21. The method, composition, antibody or antigen-binding fragment thereof or use of paragraph 20, wherein said CDRs are Kabat defined CDRs, Chothia defined CDRs or AbM defined CDRs.
[Section 22]
The method or composition according to any one of items 1 to 17 and 19 to 21 above, wherein the antibody or antigen-binding fragment thereof that binds to S. aureus AT further comprises a heavy chain constant region. , antibodies or antigen-binding fragments thereof or uses.
[Section 23]
23. The method, composition, according to item 22 above, wherein said heavy chain constant region is selected from the group consisting of human immunoglobulin IgG 1 , IgG 2 , IgG 3 , IgG 4 , IgA 1 and IgA 2 heavy chain constant regions. Antibodies or antigen-binding fragments thereof or uses.
[Section 24]
23. The method, composition, antibody or antigen-binding fragment thereof, or use of paragraph 22, wherein said heavy chain constant region is a human IgG 1 constant region.
[Section 25]
22. The method or composition according to any one of items 1 to 18, 20 and 21 above, wherein the antibody or antigen-binding fragment thereof that binds to S. aureus AT further comprises a light chain constant region. , antibodies or antigen-binding fragments thereof or uses.
[Section 26]
26. The method, composition, antibody or antigen-binding fragment thereof or use of Claim 25, wherein said light chain constant region is selected from the group consisting of human immunoglobulin IgGκ and IgGλ light chain constant regions.
[Section 27]
26. The method, composition, antibody or antigen-binding fragment thereof or use of paragraph 25, wherein said light chain constant region is a human IgG kappa light chain constant region.
[Section 28]
28. The method, composition, antibody according to any one of items 1 to 27, wherein the antibody or antigen-binding fragment thereof that binds to S. aureus AT is an IgG antibody or antigen-binding fragment thereof. or an antigen-binding fragment or use thereof.
[Section 29]
29. The antibody or antigen-binding fragment thereof that binds to S. aureus AT comprises an Fc region that has been genetically engineered for improved half-life. A method, composition, antibody or antigen-binding fragment thereof or use of.
[Item 30]
30. The method, composition, antibody of any one of paragraphs 1 to 29, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus AT comprises an Fc region having a YTE mutation. or an antigen-binding fragment or use thereof.
[Item 31]
31. The method, composition, antibody or method according to any one of items 1 to 30, wherein the antibody or antigen-binding fragment thereof that binds to S. aureus AT is a monoclonal antibody or antigen-binding fragment. Antigen-binding fragments or uses thereof.
[Item 32]
32. The method, composition, antibody or antigen binding thereof of any one of the preceding paragraphs 1-31, wherein the antibody or antigen-binding fragment thereof that binds to S. aureus AT is a full-length antibody. fragment or use.
[Item 33]
32. The method, composition, antibody or antigen binding thereof according to any one of the preceding paragraphs 1 to 31, wherein said antibody or antigen binding fragment thereof that binds to S. aureus AT is an antigen binding fragment. fragment or use.
[Item 34]
Said antibodies or antigen-binding fragments thereof that bind S. aureus AT include Fab, Fab', F(ab') 2 , single chain Fv (scFv), disulfide-linked Fv, intrabody, IgGΔCH2, mini 34. The method, composition, antibody of item 33, comprising a body, F(ab') 3 , tetrabody, triabody, diabodies, DVD-Ig, Fcab, mAb 2 , (scFv) 2 or scFv-Fc or an antigen-binding fragment or use thereof.
[Item 35]
35. Any one of items 1 to 34 above, wherein the antibody or antigen-binding fragment thereof that binds to S. aureus AT has an affinity of 80 to 100 pM for S. aureus AT. A method, composition, antibody or antigen-binding fragment thereof, or use according to any one of claims 1 to 3.
[Item 36]
The antibody or antigen-binding fragment thereof that binds to S. aureus ClfA is the same S. aureus antibody comprising a VH comprising the amino acid sequence of SEQ ID NO: 20 and a VL comprising the amino acid sequence of SEQ ID NO: 34. 36. The method, composition, antibody or antigen-binding fragment thereof or use of any one of the preceding clauses 1-35, which binds to a S. aureus ClfA epitope.
[Item 37]
The antibody or antigen-binding fragment thereof that binds to S. aureus ClfA is a S. aureus antibody comprising a VH comprising the amino acid sequence of SEQ ID NO: 20 and a VL comprising the amino acid sequence of SEQ ID NO: 34 ( 37. The method, composition, antibody or antigen-binding fragment thereof, or use of any one of paragraphs 1 to 36, which competitively inhibits binding to S. aureus) ClfA.
[Item 38]
Said antibody or antigen-binding fragment that binds to S. aureus ClfA has a VH CDR1 comprising said amino acid sequence of SEQ ID NO:4, a VH CDR2 comprising said amino acid sequence of SEQ ID NO:5, said amino acid sequence of SEQ ID NO:6 VH CDR3 comprising the sequence, VL CDR1 comprising said amino acid sequence of SEQ ID NO: 13, VL CDR2 comprising said amino acid sequence of SEQ ID NO: 14, and VL CDR3 comprising said amino acid sequence of SEQ ID NO: 15. The method, composition, antibody or antigen-binding fragment thereof, or use of any one.
[Item 39]
39. The method, composition of any one of items 1 to 38, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus ClfA comprises a VH comprising said amino acid sequence of SEQ ID NO: 20. products, antibodies or antigen-binding fragments thereof or uses.
[Item 40]
40. The method, composition of any one of items 1 to 39, wherein the antibody or antigen-binding fragment thereof that binds to S. aureus ClfA comprises a VL comprising the amino acid sequence of SEQ ID NO: 34. products, antibodies or antigen-binding fragments thereof or uses.
[Item 41]
41. Any one of paragraphs 1 to 40 above, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus ClfA comprises a heavy chain constant domain comprising said amino acid sequence of CSYHLC (SEQ ID NO: 55). A method, composition, antibody or antigen-binding fragment thereof or use as described in .
[Item 42]
42. The method, composition, antibody or antigen-binding fragment thereof or use of Clause 41 above, wherein said heavy chain constant domain comprises said amino acid sequence of MHEACSYHLCQKSLSLS (SEQ ID NO: 56).
[Item 43]
43. The method of any one of paragraphs 1-42, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus ClfA comprises a heavy chain comprising said amino acid sequence of SEQ ID NO:49; Compositions, antibodies or antigen-binding fragments thereof or uses.
[Item 44]
44. The method of any one of paragraphs 1 to 43, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus ClfA comprises a light chain comprising said amino acid sequence of SEQ ID NO:53; Compositions, antibodies or antigen-binding fragments thereof or uses.
[Item 45]
Paragraphs 1 to 44 above, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus ClfA comprises VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 of SAR114-N3Y The method, composition, antibody or antigen-binding fragment thereof or use according to any one of
[Section 46]
Said antibody or antigen-binding fragment thereof that binds to S. aureus ClfA comprises VH CDR1, VH CDR2 of 11H10, SAR72, SAR80, SAR113, SAR132, SAR352, SAR372, SAR510, SAR547, SAS1, SAS19 or SAS203 , VH CDR3, VL CDR1, VL CDR2 and VL CDR3.
[Section 47]
47. The method, composition, antibody or antigen-binding fragment thereof or use of paragraphs 45 or 46, wherein said CDRs are Kabat defined CDRs, Chothia defined CDRs or AbM defined CDRs.
[Item 48]
Said antibody or antigen-binding fragment thereof that binds to S. aureus ClfA comprises VH and VL, wherein said VH is said amino acid sequence according to any one of SEQ ID NOs: 21-31 and 68 47. The method, composition, antibody or antigen-binding fragment thereof or use of any one of paragraphs 1-35 or 46 above, comprising:
[Item 49]
The antibody or antigen-binding fragment thereof that binds to S. aureus ClfA comprises a VH and a VL, wherein the VL comprises the amino acid sequence according to any one of SEQ ID NOs: 35-45 and 69. 47. The method, composition, antibody or antigen-binding fragment thereof or use of any one of paragraphs 1-35 or 46 above, comprising:
[Item 50]
Said antibody, or antigen-binding fragment thereof, that binds to S. aureus ClfA comprises (a) SEQ ID NOs: 21 and 35, respectively; (b) SEQ ID NOs: 22 and 36, respectively; (c) SEQ ID NOs: 23 and 37, respectively; (d) SEQ. , (i) SEQ ID NOs: 29 and 43, respectively, (j) SEQ ID NOs: 30 and 44, respectively, (k) SEQ ID NOs: 31 and 45, respectively, or (l) SEQ ID NOs: 68 and 69, respectively, and 36. The method, composition, antibody or antigen-binding fragment thereof or use of any one of the preceding paragraphs 1-35, comprising a VL sequence.
[Section 51]
51. The method, composition according to any one of items 1 to 40 and 44 to 50 above, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus ClfA further comprises a heavy chain constant region. , antibodies or antigen-binding fragments thereof or uses.
[Section 52]
52. The method, composition, according to paragraph 51 above, wherein said heavy chain constant region is selected from the group consisting of human immunoglobulin IgG 1 , IgG 2 , IgG 3 , IgG 4 , IgA 1 and IgA 2 heavy chain constant regions. Antibodies or antigen-binding fragments thereof or uses.
[Section 53]
52. The method, composition, antibody or antigen-binding fragment thereof or use of paragraph 51, wherein said heavy chain constant region is a human IgG 1 constant region.
[Section 54]
54. The method, composition according to any one of items 1 to 43 and 45 to 53 above, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus ClfA further comprises a light chain constant region. , antibodies or antigen-binding fragments thereof or uses.
[Section 55]
55. The method, composition, antibody or antigen-binding fragment thereof or use of Claim 54, wherein said light chain constant region is selected from the group consisting of human immunoglobulin IgGκ and IgGλ light chain constant regions.
[Section 56]
55. The method, composition, antibody or antigen-binding fragment thereof or use of paragraph 54, wherein said light chain constant region is a human IgG kappa light chain constant region.
[Section 57]
1, above, wherein said antibody or antigen-binding fragment that binds to S. aureus ClfA comprises a mutation that extends half-life in human FcRn mice compared to said same antibody without said mutation. 57. The method, composition, antibody or antigen-binding fragment thereof or use of any one of claims 1-56.
[Section 58]
Said antibody or antigen-binding fragment thereof that binds to S. aureus ClfA comprises a mutation that extends half-life relative to said same antibody without said mutation, said mutation comprising: 58. The method, composition, antibody or antigen-binding fragment thereof or use of any one of the preceding paragraphs, which does not inhibit OPK activity compared to said same antibody or antigen-binding fragment without mutation.
[Section 59]
59. A method, composition, antibody or Antigen-binding fragments or uses thereof.
[Section 60]
60. The method, composition, antibody or antigen binding thereof of any one of paragraphs 1 to 59, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus ClfA is a full-length antibody. fragment or use.
[Section 61]
60. The method, composition, antibody or antigen binding thereof of any one of paragraphs 1 to 59, wherein said antibody or antigen binding fragment thereof that binds to S. aureus ClfA is an antigen binding fragment. fragment or use.
[Section 62]
Said antibodies or antigen-binding fragments thereof that bind to S. aureus ClfA include Fab, Fab', F(ab') 2 , single chain Fv (scFv), disulfide-linked Fv, intrabody, IgGΔCH2, mini 62. The method, composition, antibody of paragraph 61, comprising a body, F(ab') 3 , tetrabody, triabody, diabody, DVD-Ig, Fcab, mAb 2 , (scFv) 2 or scFv-Fc or an antigen-binding fragment or use thereof.
[Section 63]
Item 1 above, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus ClfA has an IC50 that is within 2 μg/mL of each other for ClfA001, ClfA002 and ClfA004 in a fibrinogen binding inhibition assay. 62. The method, composition, antibody or antigen-binding fragment thereof or use of any one of claims 1-62.
[Section 64]
Said antibody or antigen-binding fragment thereof that binds to S. aureus ClfA has an IC50 against ClfA001, ClfA002 and ClfA004 all between 1 μg/mL and 5 μg/mL in a fibrinogen binding inhibition assay. 64. The method, composition, antibody or antigen-binding fragment thereof, or use of any one of the preceding paragraphs 1-63, comprising:
[Section 65]
1, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus ClfA has binding affinities (K D ) for ClfA001, ClfA002 and ClfA004 that are all between 200 and 350 pM. 64. The method, composition, antibody or antigen-binding fragment thereof or use of any one of claims 1-64.
[Section 66]
66. Any one of paragraphs 1-65 above, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus ClfA has a binding affinity (K D ) of less than 1 nM for all ClfA genotypes. The method, composition, antibody or antigen-binding fragment thereof, or use according to the clause.
[Section 67]
Said antibody or antigen-binding fragment that binds to S. aureus ClfA is reduced by 5% or less after exposure of said antibody or antigen-binding fragment to conventional white light at 2 kLux/hr at 23° C. for 14 days 67. The method, composition, antibody or antigen-binding fragment thereof or use of any one of paragraphs 1 to 66, having monomeric purity.
[Section 68]
Said antibody or antigen-binding fragment thereof binds to at least one S. aureus leukotoxin, binds LukF, LukD and/or HlgB, and/or said antibody or antigen-binding fragment thereof binds to LukF 68. The method, composition, antibody or antigen-binding fragment thereof or use of any one of the preceding paragraphs that neutralizes , LukD and/or HlgB.
[Section 69]
Said antibody or antigen-binding fragment thereof binds to at least one S. aureus leukotoxin, binds LukF, LukD and/or HlgB, and/or said antibody or antigen-binding fragment thereof binds to LukF 69. The method, composition, antibody or antigen-binding fragment thereof or use of paragraph 68 above which neutralizes , LukD and/or HlgB.
[Section 70]
The antibody or antigen-binding fragment thereof that binds to S. aureus leukotoxin has the same yellow color as the antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:32 and a VL comprising the amino acid sequence of SEQ ID NO:46. 70. The method, composition, antibody or antigen-binding fragment thereof or use of any one of the preceding clauses 1-69 that binds to a S. aureus leukotoxin epitope.
[Section 71]
The antibody or antigen-binding fragment thereof that binds to S. aureus leukotoxin is the antibody comprising a VH comprising the amino acid sequence of SEQ ID NO: 32 and a VL comprising the amino acid sequence of SEQ ID NO: 46. 71. The method, composition, antibody or antigen-binding fragment thereof or use of any one of the preceding paragraphs, which competitively inhibits binding to S. aureus leukotoxin.
[Section 72]
Said antibody or antigen-binding fragment that binds to at least one S. aureus leukotoxin comprises VH CDR1 comprising said amino acid sequence of SEQ ID NO: 7, VH CDR2 comprising said amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 9, VL CDR1 comprising said amino acid sequence of SEQ ID NO: 16, VL CDR2 comprising said amino acid sequence of SEQ ID NO: 17, and VL CDR3 comprising said amino acid sequence of SEQ ID NO: 18. 72. The method, composition, antibody or antigen-binding fragment thereof, or use of any one of 1-71.
[Section 73]
73. The above clauses 1-72, wherein said antibody or antigen-binding fragment thereof that binds to at least one S. aureus leukotoxin comprises a VH comprising said amino acid sequence of SEQ ID NO:32. A method, composition, antibody or antigen-binding fragment thereof or use as described.
[Section 74]
74. The above clauses 1-73, wherein said antibody or antigen-binding fragment thereof that binds to at least one S. aureus leukotoxin comprises a VL comprising said amino acid sequence of SEQ ID NO:46. A method, composition, antibody or antigen-binding fragment thereof or use as described.
[Section 75]
75. Any one of paragraphs 1-74 above, wherein said antibody or antigen-binding fragment thereof that binds at least one S. aureus leukotoxin comprises a heavy chain comprising said amino acid sequence of SEQ ID NO:50. A method, composition, antibody or antigen-binding fragment thereof or use as described in .
[Section 76]
76. Any one of the preceding paragraphs 1-75, wherein said antibody or antigen-binding fragment thereof that binds at least one S. aureus leukotoxin comprises a light chain comprising said amino acid sequence of SEQ ID NO:54. A method, composition, antibody or antigen-binding fragment thereof or use as described in .
[Section 77]
said antibody or antigen-binding fragment thereof that binds to at least one S. aureus leukotoxin comprises VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 of SAN481-SYT; 72. The method, composition, antibody or antigen-binding fragment thereof, or use of any one of paragraphs 1-71 above.
[Section 78]
78. The method, composition, antibody or antigen-binding fragment thereof or use of paragraph 77, wherein said CDRs are Kabat defined CDRs, Chothia defined CDRs or AbM defined CDRs.
[Section 79]
79. The above paragraphs 1-74 and 76-78, wherein said antibody or antigen-binding fragment thereof that binds at least one S. aureus leukotoxin further comprises a heavy chain constant region. A method, composition, antibody or antigen-binding fragment thereof or use of.
[Section 80]
80. The method, composition, according to clause 79, wherein said heavy chain constant region is selected from the group consisting of human immunoglobulin IgG1, IgG2, IgG3 , IgG4 , IgA1 and IgA2 heavy chain constant regions. Antibodies or antigen-binding fragments thereof or uses.
[Section 81]
80. The method, composition, antibody or antigen-binding fragment thereof or use of paragraph 79, wherein said heavy chain constant region is a human IgG 1 constant region.
[Section 82]
82. The above paragraphs 1-75 and 77-81, wherein said antibody or antigen-binding fragment thereof that binds at least one S. aureus leukotoxin further comprises a light chain constant region. A method, composition, antibody or antigen-binding fragment thereof or use of.
[Section 83]
83. The method, composition, antibody or antigen-binding fragment thereof or use of Claim 82, wherein said light chain constant region is selected from the group consisting of human immunoglobulin IgGκ and IgGλ light chain constant regions.
[Section 84]
83. The method, composition, antibody or antigen-binding fragment thereof, or use of Clause 82, wherein said light chain constant region is a human IgG kappa light chain constant region.
[Section 85]
85. The method of any one of the preceding paragraphs 1-84, wherein the antibody or antigen-binding fragment thereof that binds to at least one S. aureus leukotoxin is an IgG antibody or antigen-binding fragment thereof. , compositions, antibodies or antigen-binding fragments thereof or uses.
[Section 86]
86. Any of the above paragraphs 1-85, wherein said antibody or antigen-binding fragment thereof that binds at least one S. aureus leukotoxin comprises an Fc region that has been genetically modified for improved half-life. A method, composition, antibody or antigen-binding fragment thereof, or use according to any one of claims 1 to 3.
[Section 87]
87. The method of any one of paragraphs 1-86, wherein said antibody or antigen-binding fragment thereof that binds at least one S. aureus leukotoxin comprises an Fc region having a YTE mutation. , compositions, antibodies or antigen-binding fragments thereof or uses.
[Section 88]
88. The method of any one of the preceding paragraphs 1-87, wherein the antibody or antigen-binding fragment thereof that binds at least one S. aureus leukotoxin is a monoclonal antibody or antigen-binding fragment thereof. , compositions, antibodies or antigen-binding fragments thereof or uses.
[Section 89]
89. The method, composition of any one of the preceding paragraphs 1-88, wherein said antibody or antigen-binding fragment thereof that binds at least one S. aureus leukotoxin is a full-length antibody; Antibodies or antigen-binding fragments thereof or uses.
[Item 90]
89. The method, composition of any one of the preceding paragraphs 1-88, wherein the antibody or antigen-binding fragment thereof that binds to at least one S. aureus leukotoxin is an antigen-binding fragment; Antibodies or antigen-binding fragments thereof or uses.
[Item 91]
Said antibodies or antigen-binding fragments thereof that bind S. aureus AT include Fab, Fab', F(ab') 2 , single chain Fv (scFv), disulfide-linked Fv, intrabody, IgGΔCH2, mini 91. The method, composition, antibody of paragraph 90, comprising a body, F(ab') 3 , tetrabody, triabody, diabodies, DVD-Ig, Fcab, mAb 2 , (scFv) 2 or scFv-Fc or an antigen-binding fragment or use thereof.
[Item 92]
said antibody or antigen-binding fragment thereof that binds to at least one S. aureus leukotoxin has an affinity of less than 75 pM for S. aureus LukF, LukD and H1gB; 92. The method, composition, antibody or antigen-binding fragment thereof, or use of any one of paragraphs 1-91 above.
[Item 93]
93. Any one of paragraphs 1 to 92 above, wherein said antibody or antigen-binding fragment thereof that binds to at least one S. aureus leukotoxin has similar affinities for LukF, LukD and HIgB. The method, composition, antibody or antigen-binding fragment thereof, or use according to the clause.
[Item 94]
94. The method, composition, antibody or antigen-binding fragment thereof or use of any one of paragraphs 1, 2 and 5-93 above, wherein said S. aureus infection is sepsis.
[Item 95]
94. The method, composition, antibody or antigen-binding fragment thereof or use of any one of paragraphs 1, 2 and 5-93, wherein said S. aureus infection is bacteremia.
[Item 96]
94. The method, composition, antibody or antigen-binding fragment thereof or use of any one of paragraphs 1, 2 and 5-93 above, wherein said S. aureus infection is pneumonia.
[Item 97]
94. The method, composition, antibody or antigen-binding fragment thereof or use of any one of paragraphs 1, 2 and 5-93 above, wherein said S. aureus infection is ICU pneumonia.
[Item 98]
94. The method, composition, antibody or antigen thereof according to any one of the above items 1, 2 and 5-93, wherein the S. aureus infection is a skin or soft tissue infection (SSTI) binding fragment or use.
[Item 99]
94. The method, composition, antibody or antigen-binding fragment thereof according to any one of Items 1, 2 and 5 to 93 above, wherein the S. aureus infection is a diabetic infection of the lower extremities. or use.
[Item 100]
94. The method, composition, antibody or antigen thereof according to any one of the above items 1, 2 and 5 to 93, wherein the S. aureus infection is diabetic foot ulcer (DFU) binding fragment or use.
[Item 101]
101. The method, composition, antibody or antigen-binding fragment thereof or use of paragraph 100, wherein said DFU is non-infectious.
[Item 102]
101. The method, composition, antibody or antigen-binding fragment thereof or use of paragraph 100, wherein said DFU is infectious.
[Item 103]
101. The method, composition, antibody or antigen-binding fragment thereof, or use of paragraph 100, wherein said DFU is Grade 1, 2 or 3 DFU.
[Item 104]
94. The method, composition, antibody or antigen-binding fragment thereof of any one of 1, 2 and 5 to 93 above, or use.
[Item 105]
94. Any one of paragraphs 1, 2 and 5-93 above, wherein the S. aureus infection is a joint infection, device-associated infection, wound infection, surgical site infection or osteomyelitis. A method, composition, antibody or antigen-binding fragment thereof or use as described in .
[Item 106]
106. The method, composition, antibody or antigen-binding fragment thereof or use of any one of paragraphs 1, 2 and 5-105 above, wherein said subject is a surgical patient.
[Item 107]
107. The method, composition, antibody of any one of items 1, 2 and 5 to 106 above, wherein the S. aureus infection comprises antibiotic-resistant S. aureus. or an antigen-binding fragment or use thereof.
[Item 108]
108. The method, composition, antibody or antigen-binding fragment thereof or use of any one of paragraphs 1, 2 and 5-107 above, wherein said subject has diabetes.
[Item 109]
109. The method, composition, antibody or antigen-binding fragment thereof, or use according to any one of Items 1, 2 and 5-108 above, wherein said subject is a human.
[Item 110]
Said treating or preventing S. aureus infection comprises inhibiting aggregation of S. aureus, neutralizing toxins, inducing opsonic erosion, S. aureus ( inhibiting fibrinogen binding of S. aureus, inhibiting aggregation of S. aureus, inhibiting thromboembolic lesion formation, inhibiting S. aureus-associated sepsis or any combination of the above.
[Item 111]
said antibody or antigen-binding fragment thereof that binds S. aureus AT and said antibody or antigen-binding fragment thereof that binds S. aureus ClfA are administered in said same pharmaceutical composition; The method, composition, antibody or antigen-binding fragment thereof, or use of any one of Items 1, 2, 6-8 and 10-110 above.
[Item 112]
said antibody or antigen-binding fragment thereof that binds S. aureus AT and said antibody or antigen-binding fragment thereof that binds S. aureus ClfA are administered in said separate pharmaceutical compositions The method, composition, antibody or antigen-binding fragment thereof or use of any one of paragraphs 1, 2, 6-8 and 10-110 above.
[Item 113]
Said antibody or antigen-binding fragment thereof that binds to S. aureus AT and said antibody or antigen-binding fragment thereof that binds to at least one S. aureus leukotoxin are combined in said same pharmaceutical composition 111. The method, composition, antibody or antigen-binding fragment thereof or use of any one of paragraphs 1, 2, 6-8 and 10-110 above administered in a body.
[Item 114]
Said antibody or antigen-binding fragment thereof that binds to S. aureus AT and at least one said antibody or antigen-binding fragment thereof that binds to S. aureus leukotoxin are combined with said separate medicament The method, composition, antibody or antigen-binding fragment thereof or use of any one of paragraphs 1, 2, 6-8 and 10-110 above administered in a composition.
[Item 115]
Said antibody or antigen-binding fragment thereof that binds to S. aureus ClfA and at least one said antibody or antigen-binding fragment thereof that binds to S. aureus leukotoxin are combined in said same pharmaceutical composition 111. The method, composition, antibody or antigen-binding fragment thereof or use of any one of paragraphs 1, 2, 6-8 and 10-110 above administered in a body.
[Item 116]
Said antibody or antigen-binding fragment thereof that binds to S. aureus ClfA and at least one said antibody or antigen-binding fragment thereof that binds to S. aureus leukotoxin are combined with said separate medicament The method, composition, antibody or antigen-binding fragment thereof or use of any one of paragraphs 1, 2, 6-8 and 10-110 above administered in a composition.
[Item 117]
117. The method, composition, antibody or antigen-binding fragment thereof or use of any one of Clauses 112, 114 and 116 above, wherein said separate pharmaceutical compositions are administered simultaneously.
[Item 118]
117. The method, composition, antibody or antigen-binding fragment thereof or use of any one of Clauses 112, 114 and 116 above, wherein said separate pharmaceutical compositions are administered sequentially.
[Item 119]
Said antibody or antigen-binding fragment thereof that binds to S. aureus AT, said antibody or antigen-binding fragment thereof that binds to S. aureus ClfA and at least one S. aureus (S. aureus) aureus), wherein said antibody or antigen-binding fragment thereof that binds to leukotoxin is administered in said same pharmaceutical composition; Compositions, antibodies or antigen-binding fragments thereof or uses.
[Item 120]
A method of treating or preventing S. aureus infection in a subject with diabetes, comprising administering to said subject an antibody or antigen-binding fragment thereof that binds to S. aureus AT. method including.
[Item 121]
An antibody or antigen-binding fragment thereof that binds S. aureus AT for use in treating or preventing S. aureus infection in a subject with diabetes.
[Item 122]
Use of an antibody that binds S. aureus AT or an antigen-binding fragment thereof in said preparation of a medicament for treating or preventing S. aureus infection in a subject with diabetes.
[Item 123]
The antibody or antigen-binding fragment thereof that binds to S. aureus AT is the same S. aureus antibody as the antibody comprising a VH comprising the amino acid sequence of SEQ ID NO: 19 and a VL comprising the amino acid sequence of SEQ ID NO: 33. 123. The method, antibody or antigen-binding fragment thereof or use of any one of paragraphs 120-122, which binds to a S. aureus AT epitope.
[Item 124]
The antibody or antigen-binding fragment thereof that binds to S. aureus AT is a S. aureus antibody comprising a VH comprising said amino acid sequence of SEQ ID NO: 19 and a VL comprising said amino acid sequence of SEQ ID NO: 33 ( 124. The method, antibody or antigen-binding fragment thereof or use of any one of paragraphs 120-123, which competitively inhibits binding to S. aureus AT.
[Item 125]
Said antibody or antigen-binding fragment that binds to S. aureus AT has a VH CDR1 comprising said amino acid sequence of SEQ ID NO:1, a VH CDR2 comprising said amino acid sequence of SEQ ID NO:2, said amino acid sequence of SEQ ID NO:3 125, comprising a VH CDR3 comprising a sequence, a VL CDR1 comprising said amino acid sequence of SEQ ID NO: 10, a VL CDR2 comprising said amino acid sequence of SEQ ID NO: 11, and a VL CDR3 comprising said amino acid sequence of SEQ ID NO: 12. The method, antibody or antigen-binding fragment thereof, or use of any one.
[Item 126]
126. The method, antibody of any one of paragraphs 120-125, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus AT comprises a VH comprising said amino acid sequence of SEQ ID NO: 19. or an antigen-binding fragment or use thereof.
[Item 127]
127. The method, antibody of any one of paragraphs 120-126, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus AT comprises a VL comprising said amino acid sequence of SEQ ID NO:33. or an antigen-binding fragment or use thereof.
[Item 128]
128. The method of any one of paragraphs 120-127, wherein said antibody or antigen-binding fragment thereof that binds S. aureus AT comprises a heavy chain comprising said amino acid sequence of SEQ ID NO:47. Antibodies or antigen-binding fragments thereof or uses.
[Item 129]
129. The method of any one of paragraphs 120-128, wherein said antibody or antigen-binding fragment thereof that binds S. aureus AT comprises a light chain comprising said amino acid sequence of SEQ ID NO:52. Antibodies or antigen-binding fragments thereof or uses.
[Item 130]
125. Any of the above paragraphs 120-124, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus AT comprises VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 of MEDI4893. The method, antibody or antigen-binding fragment thereof, or use according to any one of claims 1 to 3.
[Item 131]
131. The method, antibody or antigen-binding fragment thereof or use of paragraph 130, wherein said CDRs are Kabat defined CDRs, Chothia defined CDRs or AbM defined CDRs.
[Item 132]
The method, antibody or antibody of any one of paragraphs 120-127 and 129-131 above, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus AT further comprises a heavy chain constant region. Antigen-binding fragments or uses thereof.
[Item 133]
133. The method , antibody or Antigen-binding fragments or uses.
[Item 134]
133. The method, antibody or antigen-binding fragment thereof or use of Paragraph 132, wherein said heavy chain constant region is a human IgG 1 constant region.
[Item 135]
The method, antibody or antibody of any one of paragraphs 120-128 and 130-134 above, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus AT further comprises a light chain constant region. Antigen-binding fragments or uses thereof.
[Item 136]
136. The method, antibody or antigen-binding fragment thereof or use of Paragraph 135, wherein said light chain constant region is selected from the group consisting of human immunoglobulin IgGκ and IgGλ light chain constant regions.
[Section 137]
136. The method, antibody or antigen-binding fragment thereof or use of Paragraph 135, wherein said light chain constant region is a human IgG kappa light chain constant region.
[Item 138]
138. The method, antibody or antigen thereof according to any one of paragraphs 120 to 137, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus AT is an IgG antibody or antigen-binding fragment thereof. binding fragment or use.
[Item 139]
139. Any one of paragraphs 120 to 138, wherein said antibody or antigen-binding fragment thereof that binds S. aureus AT comprises an Fc region that has been genetically engineered for improved half-life. method, antibody or antigen-binding fragment thereof or use of.
[Item 140]
140. The method, antibody or antigen thereof of any one of paragraphs 120-139, wherein said antibody or antigen-binding fragment thereof that binds S. aureus AT comprises an Fc region having a YTE mutation. binding fragment or use.
[Item 141]
141. The method, antibody or antigen binding thereof according to any one of paragraphs 120 to 140, wherein said antibody or antigen binding fragment thereof that binds S. aureus AT is a monoclonal antibody or antigen binding fragment thereof. fragment or use.
[Item 142]
142. The method, antibody or antigen-binding fragment thereof, or use of any one of paragraphs 120 to 141, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus AT is a full-length antibody. .
[Item 143]
142. The method, antibody or antigen-binding fragment thereof, or use according to any one of paragraphs 120 to 141, wherein said antibody or antigen-binding fragment thereof that binds to S. aureus AT is an antigen-binding fragment. .
[Item 144]
Said antibodies or antigen-binding fragments thereof that bind S. aureus AT include Fab, Fab', F(ab') 2 , single chain Fv (scFv), disulfide-linked Fv, intrabody, IgGΔCH2, mini 144. The method, antibody or antigen thereof according to paragraph 143, comprising a body, F(ab') 3 , tetrabody, triabody, diabody, DVD-Ig, Fcab, mAb 2 , (scFv) 2 or scFv-Fc binding fragment or use.
[Item 145]
145. Any of paragraphs 120-144 above, wherein said antibody or antigen-binding fragment thereof that binds S. aureus AT has an affinity for S. aureus AT of 80-100 pM. The method, antibody or antigen-binding fragment thereof, or use of any one of claims 1 to 3.
[Item 146]
146. The method, antibody or antigen-binding fragment thereof or use of any one of paragraphs 120-145, wherein said S. aureus infection is sepsis.
[Section 147]
146. The method, antibody or antigen-binding fragment thereof or use of any one of paragraphs 120-145, wherein said S. aureus infection is bacteremia.
[Item 148]
146. The method, antibody or antigen-binding fragment thereof or use of any one of paragraphs 120-145, wherein said S. aureus infection is pneumonia.
[Item 149]
146. The method, antibody or antigen-binding fragment thereof or use of any one of paragraphs 120-145, wherein said S. aureus infection is ICU pneumonia.
[Item 150]
146. The method, antibody or antigen-binding fragment thereof or use of any one of paragraphs 120-145, wherein said S. aureus infection is SSTI.
[Item 151]
146. The method, antibody or antigen-binding fragment thereof or use of any one of paragraphs 120 to 145, wherein said S. aureus infection is a diabetic infection of the lower extremities.
[Item 152]
146. The method, antibody or antigen-binding fragment thereof or use of any one of paragraphs 120-145, wherein said S. aureus infection is DFU.
[Item 153]
153. The method, antibody or antigen-binding fragment thereof or use of Paragraph 152, wherein said DFU is non-infectious.
[Item 154]
153. The method, antibody or antigen-binding fragment thereof or use of paragraph 152, wherein said DFU is infectious.
[Item 155]
155. The method, antibody or antigen-binding fragment thereof or use of Paragraph 154, wherein said DFU is Grade 1, 2 or 3 DFU.
[Item 156]
146. The method, antibody or antigen-binding fragment thereof or use of any one of the preceding paragraphs and paragraphs 120-145, wherein said S. aureus infection is a bone or joint infection.
[Item 157]
146. The method of any one of paragraphs 120-145, wherein the S. aureus infection is a joint infection, device-associated infection, wound infection, surgical site infection, or osteomyelitis. , antibodies or antigen-binding fragments thereof or uses.
[Item 158]
158. The method, antibody or antigen-binding fragment thereof or use of any one of paragraphs 120-157 above, wherein said subject is a surgical patient.
[Item 159]
159. The method, antibody or antigen-binding fragment thereof or use of any one of paragraphs 120 to 158, wherein said S. aureus infection comprises antibiotic-resistant S. aureus. .
[Item 160]
160. The method, antibody or antigen-binding fragment thereof or use of any one of paragraphs 120-159, wherein said subject is a human.
The following examples further illustrate the invention but, of course, should not be construed as limiting its scope in any way.
Claims (31)
(a)前記抗体又はその抗原結合断片は黄色ブドウ球菌(S.aureus)α毒素(AT)に結合する抗体又はその抗原結合断片であり、前記医薬組成物は、
(i)黄色ブドウ球菌(S.aureus)クランピング因子A(ClfA)に結合する抗体又はその抗原結合断片及び(ii)少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する抗体又はその抗原結合断片をさらに含む、
(i)黄色ブドウ球菌(S.aureus)ClfAに結合する抗体又はその抗原結合断片及び(ii)少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する抗体又はその抗原結合断片と組み合わせて投与される、又は
(i)黄色ブドウ球菌(S.aureus)ClfAに結合する抗体又はその抗原結合断片及び(ii)少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する抗体又はその抗原結合断片の一方をさらに含み、他方と組み合わせて投与される;
(b)前記抗体又はその抗原結合断片は黄色ブドウ球菌(S.aureus)ClfAに結合する抗体又はその抗原結合断片であり、前記医薬組成物は、
(i)黄色ブドウ球菌(S.aureus)ATに結合する抗体又はその抗原結合断片及び(ii)少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する抗体又はその抗原結合断片をさらに含む、
(i)黄色ブドウ球菌(S.aureus)ATに結合する抗体又はその抗原結合断片及び(ii)少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する抗体又はその抗原結合断片と組み合わせて投与される、又は
(i)黄色ブドウ球菌(S.aureus)ATに結合する抗体又はその抗原結合断片及び(ii)少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する抗体又はその抗原結合断片の一方をさらに含み、他方と組み合わせて投与される;又は
(c)前記抗体又はその抗原結合断片は少なくとも1種の黄色ブドウ球菌(S.aureus)ロイコトキシンに結合する抗体又はその抗原結合断片であり、前記医薬組成物は、
(i)黄色ブドウ球菌(S.aureus)ATに結合する抗体又はその抗原結合断片及び/又は(ii)黄色ブドウ球菌(S.aureus)ClfAに結合する抗体又はその抗原結合断片をさらに含む、
(i)黄色ブドウ球菌(S.aureus)ATに結合する抗体又はその抗原結合断片及び/又は(ii)黄色ブドウ球菌(S.aureus)ClfAに結合する抗体又はその抗原結合断片と組み合わせて投与される、又は
(i)黄色ブドウ球菌(S.aureus)ATに結合する抗体又はその抗原結合断片及び(ii)黄色ブドウ球菌(S.aureus)ClfAに結合する抗体又はその抗原結合断片の一方をさらに含み、他方と組み合わせて投与される、
医薬組成物。 1. A pharmaceutical composition for treating or preventing a Staphylococcus aureus (S. aureus) infection in a subject, comprising an antibody or antigen-binding fragment thereof,
(a) the antibody or antigen-binding fragment thereof is an antibody or antigen-binding fragment thereof that binds to S. aureus alpha-toxin (AT), and the pharmaceutical composition comprises
(i) an antibody or antigen-binding fragment thereof that binds to S. aureus clumping factor A (ClfA) and (ii) at least one antibody that binds to S. aureus leukotoxin or further comprising an antigen-binding fragment thereof,
in combination with (i) an antibody or antigen-binding fragment thereof that binds to S. aureus ClfA and (ii) at least one antibody or antigen-binding fragment thereof that binds to S. aureus leukotoxin or (i) an antibody or antigen-binding fragment thereof that binds S. aureus ClfA and (ii) at least one antibody that binds S. aureus leukotoxin or further comprising one of its antigen-binding fragments, administered in combination with the other;
(b) the antibody or antigen-binding fragment thereof is an antibody or antigen-binding fragment thereof that binds to S. aureus ClfA, and the pharmaceutical composition comprises
(i) an antibody or antigen-binding fragment thereof that binds to S. aureus AT and (ii) at least one antibody or antigen-binding fragment thereof that binds to S. aureus leukotoxin include,
in combination with (i) an antibody or antigen-binding fragment thereof that binds to S. aureus AT and (ii) at least one antibody or antigen-binding fragment thereof that binds to S. aureus leukotoxin (i) an antibody or antigen-binding fragment thereof that binds S. aureus AT and (ii) at least one antibody that binds S. aureus leukotoxin or or (c) wherein said antibody or antigen-binding fragment thereof binds at least one S. aureus leukotoxin or antibody thereof which binds to S. aureus leukotoxin an antigen-binding fragment, wherein the pharmaceutical composition comprises
(i) an antibody or antigen-binding fragment thereof that binds to S. aureus AT and/or (ii) an antibody or antigen-binding fragment thereof that binds to S. aureus ClfA,
administered in combination with (i) an antibody or antigen-binding fragment thereof that binds to S. aureus AT and/or (ii) an antibody or antigen-binding fragment thereof that binds to S. aureus ClfA or (i) an antibody or antigen-binding fragment thereof that binds to S. aureus AT and (ii) an antibody or antigen-binding fragment thereof that binds to S. aureus ClfA administered in combination with the other,
pharmaceutical composition.
(i)黄色ブドウ球菌(S.aureus)ATに結合する抗体又はその抗原結合断片及び(ii)黄色ブドウ球菌(S.aureus)ClfAに結合する抗体又はその抗原結合断片をさらに含む、
(i)黄色ブドウ球菌(S.aureus)ATに結合する抗体又はその抗原結合断片及び(ii)黄色ブドウ球菌(S.aureus)ClfAに結合する抗体又はその抗原結合断片と組み合わせて投与される、又は
(i)黄色ブドウ球菌(S.aureus)ATに結合する抗体又はその抗原結合断片及び(ii)黄色ブドウ球菌(S.aureus)ClfAに結合する抗体又はその抗原結合断片の一方をさらに含み、他方と組み合わせて投与される、
請求項1に記載の医薬組成物。 said pharmaceutical composition comprises at least one antibody or antigen-binding fragment thereof that binds to S. aureus leukotoxin;
(i) an antibody or antigen-binding fragment thereof that binds to S. aureus AT and (ii) an antibody or antigen-binding fragment thereof that binds to S. aureus ClfA,
administered in combination with (i) an antibody or antigen-binding fragment thereof that binds to S. aureus AT and (ii) an antibody or antigen-binding fragment thereof that binds to S. aureus ClfA; or further comprising one of (i) an antibody or antigen-binding fragment thereof that binds to S. aureus AT and (ii) an antibody or antigen-binding fragment thereof that binds to S. aureus ClfA, administered in combination with another,
A pharmaceutical composition according to claim 1 .
(i)配列番号1のアミノ酸配列を含む可変重鎖(VH)相補性決定領域(CDR)1、配列番号2のアミノ酸配列を含むVH CDR2、配列番号3のアミノ酸配列を含むVH CDR3、配列番号10のアミノ酸配列を含む可変軽鎖(VL)CDR1、配列番号11のアミノ酸配列を含むVL CDR2及び配列番号12のアミノ酸配列を含むVL CDR3を含む;又は
(ii)配列番号19のアミノ酸配列を含むVH及び配列番号33のアミノ酸配列を含むVLを含み;
モノクローナル抗体又はその抗原結合断片であってもよい、
請求項1又は2に記載の医薬組成物。 The antibody or antigen-binding fragment thereof that binds to S. aureus AT comprises
(i) variable heavy chain (VH) complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 1, VH CDR2 comprising the amino acid sequence of SEQ ID NO: 2, VH CDR3 comprising the amino acid sequence of SEQ ID NO: 3, SEQ ID NO: a variable light chain (VL) CDR1 comprising a ten amino acid sequence, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:11 and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:12; or (ii) comprising the amino acid sequence of SEQ ID NO:19 comprising a VH and a VL comprising the amino acid sequence of SEQ ID NO:33;
may be a monoclonal antibody or an antigen-binding fragment thereof;
3. The pharmaceutical composition according to claim 1 or 2.
(i)配列番号4のアミノ酸配列を含むVH CDR1、配列番号5のアミノ酸配列を含むVH CDR2、配列番号6のアミノ酸配列を含むVH CDR3、配列番号13のアミノ酸配列を含むVL CDR1、配列番号14のアミノ酸配列を含むVL CDR2及び配列番号15のアミノ酸配列を含むVL CDR3を含む;又は
(ii)配列番号20のアミノ酸配列を含むVH及び配列番号34のアミノ酸配列を含むVLを含み;
モノクローナル抗体又はその抗原結合断片であってもよい、
請求項1~4の何れか一項に記載の医薬組成物。 The antibody or antigen-binding fragment that binds to S. aureus ClfA comprises
(i) VH CDR1 comprising the amino acid sequence of SEQ ID NO:4, VH CDR2 comprising the amino acid sequence of SEQ ID NO:5, VH CDR3 comprising the amino acid sequence of SEQ ID NO:6, VL CDR1 comprising the amino acid sequence of SEQ ID NO:13, SEQ ID NO:14 or (ii) a VH comprising the amino acid sequence of SEQ ID NO:20 and a VL comprising the amino acid sequence of SEQ ID NO:34;
may be a monoclonal antibody or an antigen-binding fragment thereof;
The pharmaceutical composition according to any one of claims 1-4.
(i)配列番号7のアミノ酸配列を含むVHCDR1、配列番号8のアミノ酸配列を含むVH CDR2、配列番号9のアミノ酸配列を含むVH CDR3、配列番号16のアミノ酸配列を含むVL CDR1、配列番号17のアミノ酸配列を含むVL CDR2及び配列番号18のアミノ酸配列を含むVL CDR3を含む;又は
(ii)配列番号32のアミノ酸配列を含むVH及び配列番号46のアミノ酸配列を含むVLを含み;
モノクローナル抗体又はその抗原結合断片であってもよい、
請求項1~8の何れか一項に記載の医薬組成物。 said antibody or antigen-binding fragment that binds to at least one S. aureus leukotoxin,
(i) VHCDR1 comprising the amino acid sequence of SEQ ID NO: 7, VH CDR2 comprising the amino acid sequence of SEQ ID NO: 8, VH CDR3 comprising the amino acid sequence of SEQ ID NO: 9, VL CDR1 comprising the amino acid sequence of SEQ ID NO: 16, SEQ ID NO: 17 or (ii) a VH comprising the amino acid sequence of SEQ ID NO:32 and a VL comprising the amino acid sequence of SEQ ID NO:46;
may be a monoclonal antibody or an antigen-binding fragment thereof;
The pharmaceutical composition according to any one of claims 1-8.
(i)配列番号1のアミノ酸配列を含むVH CDR1、配列番号2のアミノ酸配列を含むVH CDR2、配列番号3のアミノ酸配列を含むVH CDR3、配列番号10のアミノ酸配列を含むVL CDR1、配列番号11のアミノ酸配列を含むVL CDR2及び配列番号12のアミノ酸配列を含むVL CDR3を含む;又は
(ii)配列番号19のアミノ酸配列を含むVH及び配列番号33のアミノ酸配列を含むVLを含み;
モノクローナル抗体又はその抗原結合断片であってもよい、
請求項23に記載の医薬組成物。 The antibody or antigen-binding fragment that binds to S. aureus AT comprising:
(i) VH CDR1 comprising the amino acid sequence of SEQ ID NO: 1, VH CDR2 comprising the amino acid sequence of SEQ ID NO: 2, VH CDR3 comprising the amino acid sequence of SEQ ID NO: 3, VL CDR1 comprising the amino acid sequence of SEQ ID NO: 10, SEQ ID NO: 11 or (ii) a VH comprising the amino acid sequence of SEQ ID NO: 19 and a VL comprising the amino acid sequence of SEQ ID NO: 33;
may be a monoclonal antibody or an antigen-binding fragment thereof;
24. A pharmaceutical composition according to claim 23.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862743490P | 2018-10-09 | 2018-10-09 | |
US62/743,490 | 2018-10-09 | ||
US201962833297P | 2019-04-12 | 2019-04-12 | |
US62/833,297 | 2019-04-12 | ||
PCT/US2019/055143 WO2020076789A2 (en) | 2018-10-09 | 2019-10-08 | Combinations of anti-staphylococcus aureus antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022512647A JP2022512647A (en) | 2022-02-07 |
JPWO2020076789A5 true JPWO2020076789A5 (en) | 2022-10-18 |
Family
ID=70051346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021519612A Pending JP2022512647A (en) | 2018-10-09 | 2019-10-08 | Combination of anti-Staphylococcus aureus antibody |
Country Status (11)
Country | Link |
---|---|
US (2) | US11168133B2 (en) |
EP (1) | EP3864041A2 (en) |
JP (1) | JP2022512647A (en) |
KR (1) | KR20210072057A (en) |
CN (1) | CN113164602A (en) |
AU (1) | AU2019357983A1 (en) |
BR (1) | BR112021006622A2 (en) |
CA (1) | CA3115633A1 (en) |
MX (1) | MX2021004173A (en) |
TW (1) | TW202035443A (en) |
WO (1) | WO2020076789A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE049012T2 (en) * | 2012-11-06 | 2020-09-28 | Medimmune Llc | Antibodies to s. aureus surface determinants |
US11155606B2 (en) | 2018-07-24 | 2021-10-26 | Medimmune, Llc | Antibody directed against S. aureus clumping factor a (ClfA) |
CA3115765A1 (en) | 2018-10-09 | 2020-04-16 | Medimmune, Llc | Antibodies directed against staphylococcus aureus leukotoxins |
MX2021004173A (en) | 2018-10-09 | 2021-09-08 | Medimmune Llc | Combinations of anti-staphylococcus aureus antibodies. |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
IL157041A0 (en) | 2001-01-26 | 2004-02-08 | Inhibitex Inc | Monoclonal antibodies to the clfa protein and method of use in treating and preventing infections |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
US20030226155A1 (en) | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
EP1479695B1 (en) | 2003-05-14 | 2010-02-17 | Kenta Biotech AG | Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS O6 of Pseudomonas aeruginosa |
CN1324049C (en) | 2003-08-04 | 2007-07-04 | 中国疾病预防控制中心病毒病预防控制所 | Human source anti SARS coronavirus gene engineering antibody |
SG172616A1 (en) | 2004-04-13 | 2011-07-28 | Hoffmann La Roche | Anti-p-selectin antibodies |
TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
KR20090019007A (en) | 2006-06-12 | 2009-02-24 | 나비 바이오파마슈티컬즈 | Use of alpha-toxin for treating and preventing staphylococcus infections |
WO2008103474A1 (en) | 2007-02-20 | 2008-08-28 | Anaptysbio, Inc. | Methods of generating libraries and uses thereof |
RS56743B1 (en) | 2007-08-21 | 2018-03-30 | Amgen Inc | Human c-fms antigen binding proteins |
WO2009029831A1 (en) | 2007-08-31 | 2009-03-05 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
JP2011526792A (en) | 2008-07-02 | 2011-10-20 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | TNF-α antagonist multi-target binding protein |
EP2208787A1 (en) | 2009-01-19 | 2010-07-21 | Université de Liège | A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
SG2014007637A (en) | 2009-01-29 | 2014-03-28 | Medimmune Llc | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
MX2012012859A (en) | 2010-05-05 | 2013-03-20 | Univ New York | Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof. |
BR112013020086B1 (en) | 2011-02-08 | 2020-12-08 | Medimmune, Llc | ISOLATED ANTIBODY OR ITS ANTIGEN BINDING FRAGMENT, COMPOSITION UNDERSTANDING THE ANTIBODY ANTIBODY OR FRAGMENT, KIT, USE OF AN EFFECTIVE QUANTITY OF AN ANTIBODY OR ITS ANTIGEN BINDING FRAGMENT AND THE ANTIGEN LAYING METHOD |
MX367082B (en) | 2012-11-06 | 2019-08-05 | Medimmune Llc | Methods of treating s. aureus-associated diseases. |
HUE049012T2 (en) | 2012-11-06 | 2020-09-28 | Medimmune Llc | Antibodies to s. aureus surface determinants |
US20160244511A1 (en) | 2013-10-17 | 2016-08-25 | Arsanis Biosciences Gmbh | Cross-reactive staphylococcus aureus antibody sequences |
WO2015175874A2 (en) | 2014-05-16 | 2015-11-19 | Medimmune, Llc | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
TWI719938B (en) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | Treatment of polybacterial infections |
EP3283514A1 (en) * | 2015-04-17 | 2018-02-21 | ARSANIS Biosciences GmbH | Anti-staphylococcus aureus antibody combination preparation |
WO2017075188A2 (en) | 2015-10-30 | 2017-05-04 | Medimmune, Llc | Methods of using anti-alpha toxin antibody |
US11155606B2 (en) | 2018-07-24 | 2021-10-26 | Medimmune, Llc | Antibody directed against S. aureus clumping factor a (ClfA) |
CA3115765A1 (en) | 2018-10-09 | 2020-04-16 | Medimmune, Llc | Antibodies directed against staphylococcus aureus leukotoxins |
MX2021004173A (en) | 2018-10-09 | 2021-09-08 | Medimmune Llc | Combinations of anti-staphylococcus aureus antibodies. |
-
2019
- 2019-10-08 MX MX2021004173A patent/MX2021004173A/en unknown
- 2019-10-08 EP EP19871705.0A patent/EP3864041A2/en not_active Withdrawn
- 2019-10-08 CA CA3115633A patent/CA3115633A1/en active Pending
- 2019-10-08 TW TW108136341A patent/TW202035443A/en unknown
- 2019-10-08 WO PCT/US2019/055143 patent/WO2020076789A2/en active Application Filing
- 2019-10-08 AU AU2019357983A patent/AU2019357983A1/en active Pending
- 2019-10-08 CN CN201980078574.1A patent/CN113164602A/en active Pending
- 2019-10-08 US US16/596,388 patent/US11168133B2/en active Active
- 2019-10-08 KR KR1020217013653A patent/KR20210072057A/en unknown
- 2019-10-08 BR BR112021006622-5A patent/BR112021006622A2/en unknown
- 2019-10-08 JP JP2021519612A patent/JP2022512647A/en active Pending
-
2021
- 2021-10-01 US US17/491,889 patent/US20220089699A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11203633B2 (en) | Polynucleotides encoding antibodies or antigen binding fragments thereof that bind pseudomonas perv | |
US20050288491A1 (en) | Super-humanized antibodies against respiratory syncytial virus | |
JP2022031635A5 (en) | ||
AU2002368077B2 (en) | Super humanized antibodies | |
JP2020062036A5 (en) | ||
JP2022105178A (en) | Compositions and methods for treating and preventing staphylococcus aureus infections | |
US8653242B2 (en) | Therapeutic antibodies against flagellated Pseudomonas aeruginosa | |
US20150284450A1 (en) | Combination therapies using anti-pseudomonas psl and pcrv binding molecules | |
JP2020513791A5 (en) | ||
JP2011509245A5 (en) | ||
JP2014519334A5 (en) | ||
JP2023134618A5 (en) | ||
JP2020514277A5 (en) | ||
JP2020513759A5 (en) | ||
JP2014525736A (en) | Immunoglobulin single variable domain for IgE | |
JP2024016024A5 (en) | ||
US20170183397A1 (en) | Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof | |
JP4452884B2 (en) | Antibodies and their use | |
JPWO2022044573A5 (en) | ||
JPWO2020076789A5 (en) | ||
JP2020533022A5 (en) | ||
JPWO2022114163A5 (en) | ||
JPWO2020076790A5 (en) | ||
RU2021112346A (en) | COMBINATIONS OF ANTIBODIES TO STAPHYLOCOCCUS AUREUS | |
JP2022535264A (en) | Humanized Tetraspecific Octavalent Antibodies Against Clostridium difficile A and B Toxins |